From the aDepartment of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA; bDepartment of Obstetrics, Gynecology, and Reproductive Sciences, School of Medicine, University of Pittsburgh, Pittsburgh, PA; cMagee-Womens Research Institute, Pittsburgh, PA; dDepartment of Pediatrics and Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada; eCenter for Perinatal Research, The Research Institute at Nationwide Children's Hospital, Columbus, OH; and fDepartment of Pediatrics, The Ohio State University College of Medicine, Columbus, OH.
Epidemiology. 2014 Mar;25(2):207-14. doi: 10.1097/EDE.0000000000000039.
We sought to determine the association between maternal vitamin D status at ≤26 weeks' gestation and the risk of preeclampsia by clinical subtype.
We conducted a case-cohort study among women enrolled at 12 US sites from 1959 to 1966 in the Collaborative Perinatal Project. In serum collected at ≤26 weeks' gestation (median 20.9 weeks) from 717 women who later developed preeclampsia (560 mild and 157 severe cases) and from 2986 mothers without preeclampsia, we measured serum 25-hydroxyvitamin D, over 40 years later, using liquid chromatography-tandem mass spectrometry.
Half of women in the subcohort had 25-hydroxyvitamin D (25(OH)D) >50 nmol/L. Maternal 25(OH)D 50 to 74.9 nmol/L was associated with a reduction in the absolute and relative risk of preeclampsia and mild preeclampsia compared with 25(OH)D <30 nmol/L in the crude analysis but not after adjustment for confounders, including race, prepregnancy body mass index, and parity. For severe preeclampsia, 25(OH)D ≥50 nmol/L was associated with a reduction in three cases per 1000 pregnancies (adjusted risk difference = -0.003 [95% confidence interval = -0.005 to 0.0002]) and a 40% reduction in risk (0.65 [0.43 to 0.98]) compared with 25(OH)D <50 nmol/L. Conclusions were unchanged (1) after restricting to women with 25(OH)D measured before 22 weeks' gestation or (2) with formal sensitivity analyses for unmeasured confounding.
Maternal vitamin D deficiency may be a risk factor for severe preeclampsia but not for its mild subtypes. Contemporary cohorts with large numbers of severe preeclampsia cases would be needed to confirm or refute these findings.
我们旨在通过临床亚型来确定妊娠 26 周前母体维生素 D 状态与子痫前期风险之间的关联。
我们对 1959 年至 1966 年期间在美国 12 个地点参与合作围产期项目的女性进行了病例-队列研究。在 717 名后来发生子痫前期的女性(560 名轻度和 157 名重度病例)和 2986 名未发生子痫前期的母亲的妊娠 26 周前(中位数为 20.9 周)采集的血清中,我们使用液相色谱-串联质谱法测定了 40 多年后血清 25-羟维生素 D。
子队列中有一半的女性 25-羟维生素 D(25(OH)D)>50nmol/L。与 25(OH)D<30nmol/L 相比,25(OH)D 在 50 至 74.9nmol/L 时,子痫前期和轻度子痫前期的绝对和相对风险降低,但在调整混杂因素后,包括种族、孕前体重指数和产次,这种关联不再存在。对于重度子痫前期,25(OH)D≥50nmol/L 与每 1000 例妊娠减少 3 例(调整风险差异=-0.003[95%置信区间=-0.005 至 0.0002])和风险降低 40%(0.65[0.43 至 0.98])相关,与 25(OH)D<50nmol/L 相比。结论在以下情况下仍然成立:(1)限制在妊娠 22 周前测量 25(OH)D 的女性中,或(2)进行未测量混杂因素的正式敏感性分析。
母体维生素 D 缺乏可能是重度子痫前期的危险因素,但不是轻度子痫前期的危险因素。需要有大量重度子痫前期病例的当代队列来证实或反驳这些发现。